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CREB is a prototypic bZIP transcription factor and a master regulator of glucose metabolism, synaptic plasticity, cell
growth, apoptosis, and tumorigenesis. Transducers of regulated CREB activity (TORCs) are essential transcriptional
coactivators of CREB and an important point of regulation on which various signals converge. In this study, we report on
the activation of TORC1 through MEKK1-mediated phosphorylation. MEKK1 potently activated TORC1, and this
activation was independent of downstream effectors MEK1/MEK2, ERK2, JNK, p38, protein kinase A, and calcineurin.
MEKK1 induced phosphorylation of TORC1 both in vivo and in vitro. Expression of the catalytic domain of MEKK1 alone
in cultured mammalian cells sufficiently caused phosphorylation and subsequent activation of TORC1. MEKK1 physi-
cally interacted with TORC1 and stimulated its nuclear translocation. An activation domain responsive to MEKK1
stimulation was mapped to amino acids 431–650 of TORC1. As a physiological activator of CREB, interleukin 1 triggered
MEKK1-dependent phosphorylation of TORC1 and its consequent recruitment to the cAMP response elements in the
interleukin 8 promoter. Taken together, our findings suggest a new mechanism for regulated activation of TORC1
transcriptional coactivator and CREB signaling.
INTRODUCTION
cAMP response element-binding protein (CREB) is one of
the most well-characterized transcription factors (Shaywitz
and Greenberg, 1999). In response to a variety of stimuli
including mitogens, neurotransmitters, and other agents
that elevate intracellular cAMP or Ca2 levels, CREB is
activated rapidly through phosphorylation at S133 in the
kinase inducible domain (KID), leading to up-regulated
transcription of more than 4000 target genes that have a
significant impact on many aspects of cell physiology and
pathology (Mayr and Montminy, 2001).
In addition to induced phosphorylation at S133, CREB
activity can also be regulated through a new family of tran-
scriptional coactivators, termed transducers of regulated
CREB activity (TORCs; Conkright et al., 2003; Iourgenko et
al., 2003). Three members named TORC1, TORC2, and
TORC3 have been found in this family. All three TORCs
activate CREB-dependent transcription, but are differen-
tially expressed in different tissues and cells (Conkright et al.,
2003). TORCs represent a critical regulatory point in a com-
plex network of signals (Bittinger et al., 2004; Sceraton et al.,
2004; Koo et al., 2005; Shaw et al., 2005; Katoh et al., 2006). In
one model for the regulation of TORC activity, tumor sup-
pressor protein LKB1, which is frequently inactivated in the
cancer-predisposing Peutz-Jeghers syndrome (Alessi et al.,
2006), can phosphorylate and activate AMP-activated pro-
tein kinase (AMPK). The AMPK kinases then phosphorylate
TORCs, leading to inhibition of O-glycosylation, binding
with 14-3-3 proteins, sequestration in the cytoplasm, and
prevention of transcriptional activation (Takemori et al.,
2007a; Dentin et al., 2008). It is noteworthy that S171-phos-
phorylated TORC2 retained in the cytoplasm undergoes
polyubiquitination at K628 followed by proteosome-depen-
dent degradation (Dentin et al., 2007). In addition, other
secondary messengers such as calcium and cAMP can also
regulate TORC activity (Screaton et al., 2004; Ohmae et al.,
2006; Amelio et al., 2007). While dephosphorylation of
TORC2 at S171 and S275 is induced by a calcium-activated
phosphatase known as calcineurin (Jansson et al., 2008),
cAMP stimulates protein kinase A (PKA)-mediated phos-
phorylation of an AMPK-related kinase termed salk-induc-
ible kinase 2 (SIK2) at S587, leading to its inhibition and
subsequent activation of TORCs (Screaton et al., 2004).
Both TORC and p300 families of transcriptional coactiva-
tors are essential for optimal activity of CREB (Siu et al.,
2006). TORCs and p300/CREB-binding protein (CBP) acti-
vate transcription through different mechanisms, but they
also synergize with each other (Ravnskjaer et al., 2007).
While phosphorylation of CREB at S133 promotes the re-
cruitment of p300/CBP but not TORCs, TORCs enhance the
association of CREB with TAFII130 independent of S133
phosphorylation (Conkright et al., 2003). On the other hand,
TORC2 binds CBP/p300 directly and cooperates with them
to confer specificity in the activation of CREB target genes
(Ravnskjaer et al., 2007).
The physiological and pathological roles of TORC coacti-
vators have been demonstrated in different contexts. First,
TORC2 is a key regulator of cell metabolism. It is a sensor of
glucose and modulates gluconeogenesis and insulin signal-
ing (Canettieri et al., 2005; Koo et al., 2005; Dentin et al., 2007,
2008). TORCs are also transcriptional activators of peroxi-
some proliferator–activated receptor  coactivator 1
(PGC1), which regulates mitochondrial biogenesis and en-
ergy metabolism (Wu et al., 2006), and steroidogenic acute
regulatory protein (StAR), a mitochondrial protein that trans-
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fers cholesterol (Takemori et al., 2007b). In addition, TORC2
coordinates glucose-dependent insulinotropic polypeptide
(GIP)-induced expression of antiapoptotic BCL2 gene (Kim et al.,
2008). Second, TORC2 regulates the normal program of ger-
minal center gene activation and repression to promote B-
cell development (Kuraishy et al., 2007). Third, TORC1 is
required for late-phase long-term synaptic potentiation in
the hippocampus (Zhou et al., 2006; Kova´cs et al., 2007).
Finally, TORCs are critically involved in tumorigenesis (Siu
and Jin, 2007). TORC1-MAML2 is a fusion oncoprotein
found in malignant salivary gland tumor and promotes
oncogenesis through activating CREB and its target genes
(Coxon et al., 2005; Wu et al., 2005). TORCs are also essential
coactivator of the Tax oncoprotein of human T-cell leukemia
virus type 1 (HTLV-1) in the activation of viral long-terminal
repeats (Koga et al., 2004; Siu et al., 2006), and this coactiva-
tion is inhibited by BCL3 (Hishiki et al., 2007). Suffice it to
say, TORC coactivators are important regulators of CREB
relevant to many biological systems and human diseases.
Different stimuli of CREB converge on just a few signaling
pathways governed by calcium, cAMP, and mitogen-acti-
vated protein kinase (MAPK; Johannessen et al., 2004).
MAPKs are evolutionarily conserved kinases that link extra-
cellular signals ultimately to nuclear transcriptional machin-
ery. MAPK modules generally comprise of three tiers in
which a specific MAPK is regulated by a MAPK kinase
(MAP2K), which in turn is activated by a MAPK kinase
kinase (MAP3K; Turjanski et al., 2007). Mitogen-activated/
extracellular signal–regulated kinase kinase 1 (MEKK1) is a
MAP3K that regulates c-Jun N-terminal kinase (JNK) as well
as other kinases including extracellular signal-regulated ki-
nases (ERK1/2), p38, and IB kinases (IKK; Cuevas et al.,
2007). MEKK1 contains a large N-terminal regulatory do-
main and a C-terminal catalytic domain (Xu et al., 1996). The
cleavage of MEKK1 at D874 releases the active kinase do-
main, resulting in constitutive activation of the kinase (Gib-
son et al., 1999). MEKK1 is a known regulator of several
transcriptional activators and coactivators such as c-Myc,
c-Jun, p53, CCAAT/enhancer binding protein  (C/EBP),
silencing mediator for retinoid and thyroid hormone recep-
tors (SMRT), and p300 (Fuchs et al., 1998; Hong and Prival-
sky, 2000; See et al., 2001; Alarcon-Vargas et al., 2002; Roy et
al., 2002; Xia et al., 2007).
To investigate whether and how MAPK might impact on
TORC activation, in this study we screened a panel of
MAPK, MAP2K, and MAP3K and identified MEKK1 as a
potent activator of TORC1-mediated transcription. The
mechanism of MEKK1-induced activation of TORC1 was
further investigated. We demonstrated the ability of MEKK1
to induce phosphorylation of TORC1, which does not occur
at S167 equivalent to S171 of TORC2. In addition, we found
that the expression of MEKK1 caused nuclear translocation of
TORC1, followed by its recruitment to the cAMP response
element (CRE) in the promoter region. Our work suggests a
new signaling pathway for the activation of TORCs and CREB.
MATERIALS AND METHODS
Plasmids
Eukaryotic and bacterial expression plasmids for TORC1 have been described
elsewhere (Siu et al., 2006). TORC1 S167A mutant was constructed by PCR
method using primers 5-GAGAAGGACCAATGCTGACTCCGCCCTGCA-3
and 5-TGCAGGGCGGAGTCAGCATTGGTCCTTCTC-3. Expression plas-
mids for hemagglutinin (HA)-tagged MEKK1 and MEKK1 D1369A (Xu et al.,
1996) were kindly provided by Dr. Melanie Cobb (The University of Texas
Southwestern Medical Center, Dallas, TX). Expression plasmid for myc-
tagged MEKK-C was constructed by subcloning MEKK-C gene in the pFC-
MEKK plasmid (Stratagene, La Jolla, CA) into pCMV-Tag3B (Stratagene) via
BamHI and XhoI restriction sites. Expression plasmids for ERK2, JNK, and
p38 (Teramoto et al., 1996; Jin et al., 1997) were kindly provided by Dr. Silvio
Gutkind (National Institute of Dental and Craniofacial Research, Bethesda,
MD). Expression vectors for TORC1 and its truncated mutants fused to Gal4
DNA-binding domain (e.g., GalTORC1, GalM1, and GalM4) were derived
from pM (Clontech, Mountain View, CA). Expression vectors for shGFP and
shTORC1a, which target green fluorescent protein (GFP) and TORC1 tran-
scripts, respectively, have been described elsewhere (Siu et al., 2006; Kok et al.,
2007). An additional short hairpin RNA (shRNA) against TORC1 designated
shTORC1b was also constructed, and it targets nucleotides 1738–1758 (5-
CAGUGGCAUCCCCAACAUCAU-3) of TORC1 mRNA. An expression vec-
tor for A-CREB, a dominant inactive version of CREB (Ahn et al., 1998), was
kindly provided by Dr. Charles Vinson (National Institute of Neurological
Disorders and Stroke, Bethesda, MD). An expression plasmid for MEKK-KR,
a dominant inactive mutant of MEKK-1 (Yan et al., 1994), was kindly provided
by Dr. Dennis Templeton (University of Virginia, Charlottesville, VA).
Reporter Assay
HeLa and HEK293 cells were cultured in DMEM and transfected with Gene-
juice transfection reagent (EMD Chemicals, Gibbstown, NJ). Cells were har-
vested 48 h after transfection. Luciferase activity was determined as described
(Ching et al., 2006; Siu et al., 2006) using the Dual-Luciferase reagents (Pro-
mega, Madison, WI). Transcriptional activity on canonical CRE or Gal4-
binding elements was measured with plasmids pCRE-Luc (Stratagene) and
pGal-Luc (Clontech), respectively. A plasmid containing 1481 to 44 nu-
cleotides of the promoter region of interleukin 8 (IL-8) gene (Mukaida et al.,
1990) was kindly provided by Dr. Naofumi Mukaida (Kanazawa University,
Kanazawa, Japan). The IL-8 promoter was subcloned into pGL3-basic (Pro-
mega) via XhoI and HindIII restriction sites to generate pIL8-Luc. Plasmid
pIL8CRE-Luc in which the CRE is disrupted was constructed by PCR method
using primers 5-AATTTCCTCTCGATCAATGAAAAGATGAGGGT-3 and 5-
ATCTTTTCATTGATCGAGAGGAAATTCCACGA-3. Transfection efficiencies
were normalized to a control plasmid (pSV-RLuc from Promega) expressing
Renilla luciferase.
Western Blotting
HeLa and HEK293 cells were lysed in lysis buffer (20 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM -glycerophosphate, and 1 mM sodium vanadate)
supplemented with protease inhibitor (Roche, Indianapolis, IN). Samples
were separated by SDS-PAGE and transferred onto Immobilon-P membranes
(Millipore, Billerica, MA). Membranes were blocked with 5% nonfat milk and
then probed with primary antibody and horseradish peroxidase–conjugated
secondary antibody. Proteins were visualized by enhanced chemilumines-
cence (Amersham, Piscataway, NJ). For alkaline phosphatase (AP) treatment
before SDS-PAGE and Western blotting, cell lysates were incubated with 10 U
of calf intestinal AP (Invitrogen, Carlsbad, CA) at 30°C for 1 h.
In Vitro Kinase Assay
Phosphorylation of TORC1 by MEKK-C in vitro was assayed essentially as
described (Jin et al., 1999). Escherichia coli–produced His-tagged TORC1 pro-
tein was affinity-purified through nickel-nitrilotriacetic acid resin (Qiagen,
Valencia, CA). Myc-tagged MEKK-C protein was immunoprecipitated from
cultured HeLa cells with rabbit anti-Myc (Santa Cruz Biotechnology, Santa
Cruz, CA). Briefly, 1 g of recombinant TORC1 was mixed with MEKK-C
precipitate in kinase buffer (25 mM Tris-HCl, pH 7.5, 0.02 mM EGTA). The
reaction was started with the addition of 10 Ci [-32P]ATP. After incubation at
30°C for 20 min, phosphorylation was terminated by the addition of sample
buffer (60 mM Tris, 2% SDS, 6% glycerol, 1% -mercaptoethanol, and 0.002%
bromophenol blue). Samples were separated by SDS-PAGE and detected by
autoradiography.
Coimmunoprecipitation
HEK293T cells grown in a 100-mm Petri dish were harvested in 0.5 ml lysis
buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.1% NP-40, and 0.5 mM
EDTA). V5-tagged TORC1 was immunoprecipitated from the cleared lysate
by overnight incubation at 4°C with rabbit anti-V5 (Sigma-Aldrich, St. Louis,
MO). The immunocomplex was collected by protein A agarose (Invitrogen),
washed three times with lysis buffer, and resuspended with SDS-PAGE
loading buffer.
Confocal Microscopy
Multicolor immunofluorescence imaging was performed on a Zeiss
LSM510 confocal microscope as described (Carl Zeiss, Thornwood, NY;
Chan et al., 2006; Ching et al., 2006). HeLa cells were fixed and permeabil-
ized with ice-cold methanol:acetone (1:1) for 10 min. Cells were blocked
with 3% bovine serum albumin (BSA) for 20 min. Cells were incubated
with primary and conjugated secondary antibodies for 1 h individually in
0.3% BSA. Cells were stained with 0.5 g/ml 4,6-diamidino-2-phenylin-
dole (DAPI) before mounting.
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RT-PCR
Semiquantitative analysis of IL-8 transcript by RT-PCR was performed as previ-
ously described (Choy et al., 2008a). Total RNA was purified by using Trizol
reagent (Invitrogen). cDNA was synthesized by using ThermoScript RT-PCR
System (Invitrogen). Primers for amplification of IL-8 mRNA were 5-ATGACT-
TCCAAGCTGGCCGTGGCTC-3 and 5-TAATTTCTGTGTTGGCGCAGTGTGG-
3. Transcript of GAPDH was amplified with primers 5-GCAGGGGGGAGC-
CAAAAGGG-3 and 5-TGCCAGCCCCAGCGTCAAAG-3. Amplification of
TORC1 mRNA was carried out with primers 5-CCCACCTTCCCTGCA-3 and
5-CTGGCCAGGGTTCTC-3. The number of PCR cycles was optimized to en-
sure that DNA amplification is within a quantitative linear range.
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR was carried out as described (Choy et al., 2008a).
Amounts of mRNA transcripts were measured by using Bio-Rad CFX96 real-
time PCR detection system (Bio-Rad, Hercules, CA). SYBR Green PCR master
mix (Applied Biosystems, Foster City, CA) was used to detect double-stranded
DNA. Relative expression levels of TORC1 mRNA were calculated by normal-
izing to the level of GAPDH mRNA by using comparative threshold cycle (ct)
method, in which fold difference 2(ct of target genect of reference). Primers for
amplification of TORC1 mRNA were 5-GCCTCTGATGTGGTCTCTTCC-3 and
5-CCACGCAGC CAGAATCCTTTAG-3. GAPDH transcript was amplified
with primers 5-AACGTGTCAGTGGTGGACCTG-3 and 5-AGTGGGT-
GTCGCTGTTGAAGT-3.
Northern Blotting
Northern blot analysis of IL-8 mRNA was carried out as described (Choy et
al., 2008b). Briefly, total RNA of HeLa cells was extracted by using RNeasy
reagents (Qiagen). RNA was immobilized onto Zeta-Probe GT membrane
(Bio-Rad) by UV cross-linking. IL-8 and GAPDH probes were generated with
the same primers listed above for RT-PCR analysis. These gene-specific
probes were labeled with [-32P]dCTP (Applied Biosystems) using Ready-
To-Go DNA Labeling beads (Amersham). Unincorporated nucleotides were
removed by using illustra ProbeQuant G-50 microcolumns (GE Healthcare,
Piscataway, NJ). Membrane was hybridized with labeled probes in Northern-
Max prehybridization and hybridization buffer (Ambion, Austin, TX) at 42°C
overnight. After hybridization, the blot was rinsed twice with 2 SSC con-
taining 0.1% SDS at 42°C for 5 min and then washed twice with 0.1 SSC
containing 0.1% SDS at 42°C for 15 min.
Chromatin Immunoprecipitation Assay
The association of TORC1 with IL-8 promoter in cultured cells was detected
by the chromatin immunoprecipitation (ChIP) assay as described (Chun and
Jin, 2003; Chin et al., 2005). Briefly, HeLa cells were cross-linked by 1%
formaldehyde for 10 min at 37°C. The DNA–protein complex was immuno-
precipitated, and the genomic DNA was purified by phenol-chloroform ex-
traction. Promoter sequence spanning 121 to 62 nucleotides of the IL-8
gene was PCR-amplified by using primers 5-GGGCCATCAGTTG-
CAAATCGT-3 and 5-TTCCTTCCGGTGGTTTCTTC-3.
RESULTS
MEKK1 Activates TORC1-mediated Transcription
Although MAPKs are critically involved in the regulation of
CREB activation, the underlying mechanisms are not well
understood (Johannessen et al., 2004). To investigate
whether and how MAPKs, MAP2Ks, and MAP3Ks might
modulate the activation of TORCs, we screened a panel of 13
kinases (ERK1, ERK2, JNK, p38, ERK5, MEK1, MEK2,
MEK4, MEK7, MEKK1, MEKK3, Raf, and ASK1) for stimu-
lation of TORC1-dependent activation of CRE-driven ex-
pression of firefly luciferase reporter. Because MEKK1 ex-
hibited the most significant stimulatory activity on TORC1
among the 13 kinases tested, we sought to characterize its
activation of TORC1 in detail.
We first performed cotransfection experiments to assess
MEKK1-induced activation of TORC1-dependent transcrip-
tion. In HeLa cells where the level of endogenous TORCs
was low (Conkright et al., 2003), the expression of MEKK1
alone, when compared with that of TORC1, did not signif-
icantly activate CRE-driven transcription (Figure 1; groups
1–4 compared with group 5). In contrast, when TORC1 and
MEKK1 were coexpressed, MEKK1 induced moderate and
dose-dependent enhancement of TORC1 activity on CRE
(Figure 1A; groups 5–8). Because MEKK1 is a MAP3K, we
next investigated the requirement of the kinase activity for
the activation of TORC1 by using two forms of MEKK1.
First, we used constitutively active MEKK-C that contains
the catalytic domain only. More than 10-fold stimulation of
Figure 1. Activation of TORC1 transcriptional activity by MEKK1. HeLa cells were transfected with the indicated plasmids. All groups
received reporter constructs pCRE-Luc and pSV-RLuc. TORC1 (A–C) or TORC1 S167A (D–F) expression plasmid was also introduced into
cells in groups 5–8. The amounts of expression vector for full-length MEKK1 (A and D), MEKK-C (B and E), and MEKK1 D1369A (C and
F) were progressively increased as indicated. Relative luciferase activity (RLA) represents firefly luciferase activity recovered form pCRE-Luc
normalized to Renilla luciferase activity recovered from pSV-RLuc. Results represent three independent experiments; error bars, SDs.
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TORC1 transcriptional activity by MEKK-C (Figure 1B;
groups 5–8) suggested that the activation of TORC1 was
likely triggered by an MEKK1-induced phosphorylation
event. Similar findings were also obtained from HEK293
cells (Supplemental Figure S1; groups 5–8), indicating that
MEKK1-dependent activation of TORC1 occurred in differ-
ent types of cells. Second, we exploited MEKK1 D1369A, a
kinase-dead mutant of MEKK1 (Xu et al., 1996). The inability
of MEKK1 D1369A to stimulate TORC1-mediated transcrip-
tion (Figure 1C, groups 5–8) lent further support to the
notion that MEKK1-induced phosphorylation mediates the
activation of TORC1.
The regulation of TORC1 through phosphorylation at
S167 by AMPK-related kinases such as SIK2 has been sug-
gested (Screaton et al., 2004). To determine the involvement
of this phosphorylation in MEKK1-induced activation of
TORC1, we constructed the S167A mutant of TORC1 and
characterized it for activity on CRE and stimulation by
MEKK1. Because the behaviors of TORC1 wild-type and
TORC1 S167A in all three settings of the reporter assay were
almost identical (Figure 1, D–F, compared with A–C),
MEKK1-induced activation of TORC1 was independent of
phosphorylation at S167.
TORC1-activated Transcription Is Not Mediated by
ERK2, MEK1/2, JNK, p38, PKA, or Calcineurin
MEKK1 is a MAP3K that activates downstream MAPKs
such as ERK2, JNK, and p38 (Turjanski et al., 2007). In our
initial screening for activators of TORC1, none of these
MAPKs was found to stimulate TORC1-induced activation
of CRE-dependent transcription. To formally address the in-
fluence of MAPKs on TORC1 activity, we measured TORC1
transcriptional activity with progressively increasing doses of
ERK2, JNK, and p38 (Figure 2, A–C; lanes 5–8). Although
expression of ERK2 and JNK did not affect TORC1 activity
significantly, TORC1 appeared to be inhibited in high concen-
trations of p38, which was likely caused by cytotoxicity.
To determine whether downstream kinases MEK1/2, JNK
and p38 are involved in MEKK1-dependent activation of
TORC1, we also used chemical inhibitors U0126, SP600125,
and SB203580, which specifically block MEK1/2, JNK, and
p38 activity, respectively (Clerk and Sugden, 1998; Favata et
al., 1998; Bennett et al., 2001). To prevent nonspecific effect on
the CRE, we tethered TORC1 to the promoter through Gal4
DNA-binding domain and stimulated with MEKK-C. In this
setting, an approximately twofold activation of GalTORC1
by MEKK-C was observed (Figure 2D, groups 1–4). How-
ever, neither the basal activity of GalTORC1 nor the stimu-
lation by MEKK-C was significantly affected by U0126,
SP600125, or SB203580 (Figure 2D, groups 5–8, 9–12, and
13–16). Consistent with this, the addition of U0126,
SP600125, or SB203580 did not influence TORC1-induced
activation of CRE-dependent transcription (Supplemental
Figure S2, A–D). Thus, MEKK1-induced activation of
TORC1-dependent transcription was unlikely mediated
through MEK1/2, ERK2, JNK, or p38.
Coactivator function of TORCs is regulated by PKA and
calcineurin (Screaton et al., 2004; Jansson et al., 2008), which
could also be activated directly or indirectly by MEKK1. To
exclude the possibility that PKA and calcineurin might be
involved in MEKK1-induced activation of TORC1, we also
assessed the impact of PKA and calcineurin inhibitors on the
activation of GalTORC1 by MEKK-C. H89 is a specific in-
hibitor of PKA (Chijiwa et al., 1990), whereas cyclosporin A
(CsA) potently inhibits calcineurin (Liu et al., 1991). Notably,
treatment of cells with H89 or CsA did not alter the activity
profile of GalTORC1 in the presence or in the absence of
MEKK-C (Figure 2D, groups 17–20 and 21–24). In addition,
neither H89 nor CsA exerted a significant effect on the
activation of CRE-dependent transcription by TORC1 (Sup-
plemental Figure S2, E and F). Hence, PKA or calcineurin is
not involved in MEKK1-induced activation of TORC1.
MEKK1 Induces S167-independent Phosphorylation of
TORC1
Activation of TORC1 by MEKK1 prompted us to determine
whether MEKK1 sufficiently induced phosphorylation of TORC1
in vivo and in vitro. We overexpressed TORC1 and MEKK1 in
HeLa cells and monitored the status of TORC1 proteins by
Western blotting. While a doublet TORC1 band was ob-
served in the lysate of cells expressing TORC1 alone (Figure
3, A and B; lane 1), expression of MEKK1 or dominant active
Figure 2. TORC1- and MEKK1-mediated tran-
scriptional activation is not mediated through
ERK2, JNK, p38, PKA, or calcineurin. HeLa cells
were transfected with the indicated plasmids and
RLA was measured as in Figure 1. Progressively
increasing amounts of expression vector for full-
length ERK2 (A), JNK (B), p38 (C), and MEKK-C
(D) were used. The indicated inhibitors (U0126,
SP600125, SB205380, H89, and CsA) were added
from a stock solution in DMSO to the cell culture
to a final concentration of 5 M at 14 h before
harvest.
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MEKK-C resulted in the accumulation of the slow-migrating
TORC1 species (Figure 3, A and B; lane 2). To verify that the
slow-migrating band represents hyperphosphorylated
form of TORC1 (pTORC1), we treated the protein samples
with AP before SDS-PAGE analysis. Disappearance of the
slow-migrating band and emergence of the fast-migrating
species in the presence of AP indicated that TORC1 was
indeed phosphorylated upon expression of MEKK1 or
MEKK-C (Figure 3, A and B, lane 3). In contrast, no alter-
ation of the doublet TORC1 band pattern was appreciated
when the kinase-deficient mutant MEKK1 D1369A was ex-
pressed (Figure 3C). Additionally, similar results were also
obtained from HEK293 cells (Supplemental Figure S3). Thus,
the kinase activity of MEKK1 was required for phosphory-
lation of TORC1.
We next carried out in vitro kinase assay with recombi-
nant TORC1 and MEKK1 proteins. Despite many attempts,
MEKK1 proteins either purified from E. coli or purchased
from different sources were found to be inactive in the
phosphorylation of myelin basic protein (MBP). In light of
this, we expressed Myc-tagged MEKK-C in HeLa cells and
immunoprecipitated MEKK-C protein with a mAb against
Myc. As shown in Figure 3D, incubation of recombinant
TORC1 purified from E. coli with MEKK-C precipitated from
HeLa cells led to phosphorylation of TORC1.
Because TORC1 is thought to be phosphorylated at S167
equivalent to S171 of TORC2 (Screaton et al., 2004), we
expressed TORC1 S167A in HeLa and HEK293 cells and
repeated the phosphorylation assays with MEKK1,
MEKK-C, and MEKK1 D1369A (Figure 4 and Supplemental
Figure 4. MEKK1-induced and S167-independent
phosphorylation of TORC1. Phosphorylation of TORC1
S167A in HeLa cells expressing MEKK1, MEKK-C, and
MEKK1 D1369A (A–C) was analyzed as in Figure 3.
Figure 3. MEKK1-induced phosphorylation of TORC1.
(A–C) TORC1 phosphorylation in HeLa cells expressing
MEKK1,MEKK-C, andMEKK1D1369A. Cells were trans-
fected with expression plasmids for TORC1 and full-
length MEKK1 (A), MEKK-C (B), or MEKK1 D1369A (C).
Cell lysate in lane 3 was treated with alkaline phosphatase
(AP). TORC1, MEKK1, and MEKK-C were detected with
anti-V5, anti-HA, and anti-Myc antibodies, respectively.
-Tubulin was also probed to verify equal loading.
pTORC1 represents hyperphosphorylated form of TORC1
protein. (D) MEKK-C–mediated phosphorylation of
TORC1 in vitro. E. coli–produced His-tagged TORC1
(lanes 2 and 3) was incubated with MEKK-C recovered
from HeLa cells (lanes 1 and 3). Phosphorylated TORC1
was analyzed by SDS-PAGE followed by autoradiography.
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Figure S4). It is noteworthy that the patterns of pTORC1
S167A and TORC1 S167A proteins observed were very sim-
ilar to those of pTORC1 and TORC1 (compare Figure 4 with
Figure 3 and Supplemental Figure S4 to Supplemental Fig-
ure S3). Hence, MEKK1-induced phosphorylation of TORC1
did not occur at the S167 phosphorylation site.
MEKK1 Interacts with TORC1 and Relocalizes It to the
Nucleus
The induction of TORC1 phosphorylation by MEKK1 in
vivo and in vitro (Figures 3 and 4 and Supplemental Figures
S3 and S4) led us to examine whether these two proteins
might associate with each other. When we performed a
coimmunoprecipitation assay in HeLa cells expressing
TORC1 and MEKK1, a protein complex of TORC1 and
MEKK1 was detected (Figure 5, lane 4). This association
between TORC1 and MEKK1 was specific because copre-
cipitation did not occur when either TORC1 or MEKK1
alone was expressed (Figure 5, lanes 2 and 3).
To verify the interaction of TORC1 and MEKK1, we went
on to determine their subcellular localizations in HeLa cells.
We noted that both MEKK1 and TORC1 localized to the
cytoplasm (Figure 6, panels 1–4). Interestingly, while
MEKK1 D1369A did not influence the distribution of TORC1
within the cell (Figure 6, panels 5–8), dominant active
MEKK-C was predominantly found in the nucleus, and it
relocalized TORC1 to intranuclear compartment (Figure 6,
panels 9–12). These results were compatible with the notion
that MEKK1-induced phosphorylation of TORC1 promotes
nuclear translocation.
MEKK1-induced Phosphorylation Is Mediated through a
C-terminal Activation Domain in TORC1
Although the C-terminal 200 amino acids of TORC1 have
been thought to be important for transcriptional activity
(Conkright et al., 2003), it is not understood whether they can
sufficiently mediate transcriptional activation. To address
this issue, we constructed a series of truncated mutants of
TORC1 (Figure 7A) and expressed them in HEK293T cells as
Gal4 DNA-binding domain fusions. Results from luciferase
reporter assays indicated that a C-terminal domain comprising
amino acids 431–650 was sufficient for transcriptional activa-
tion (Figure 7B, group 6 compared with groups 1 and 2).
Consistent with this, a C-terminal-truncated TORC1 mutant
deprived of amino acids 441–650 exhibited a substantially re-
duced transcriptional activity on CRE (Supplemental Figure
S5, group 5 compared with group 2). Interestingly, the tran-
scriptional activity of GalM4 containing the C-terminal activa-
tion domain only could be further stimulated by MEKK-C
(Figure 7C, groups 21–24 compared with groups 1–4 and 5–8).
Thus, this C-terminal activation domain likely contains the
site(s) that are modified by MEKK1-induced phosphorylation.
To verify the modification of GalM4 in response to
MEKK1, we coexpressed GalM4 and MEKK-C in HEK293T
cells. Indeed, slow-migrating GalM4 bands were observed in
MEKK-C–expressing cells (Figure 7D, lane 2 compared with
lane 1). Treatment with AP confirmed that the slow-migrat-
ing GalM4 species were hyperphosphorylated forms,
whereas the single band seen in the absence of MEKK-C was
derived from hypophosphorylated GalM4 (Figure 7D, lane 3
compared with lanes 2 and 1). Together, our results demon-
strated that MEKK1-induced phosphorylation occurs within
the C-terminal activation domain of TORC1.
Physiological Activation of IL-8 Promoter Is Mediated
through MEKK1 and TORC1
Above we demonstrated MEKK1 activation of TORC1-de-
pendent transcription on canonical CRE (Figures 1 and 2).
This raised a major concern about the physiological rele-
vance of our findings. To address this issue, we chose IL-8
promoter for further analysis because IL-8 was one of
cAMP-responsive genes initially identified in the functional
Figure 5. Interaction of MEKK1 with TORC1 in cultured cells.
HeLa cells were transfected with expression plasmids for V5-tagged
TORC1 (lanes 3 and 4) and HA-tagged MEKK1 (lanes 2 and 4).
TORC1 was immunoprecipitated with anti-V5. The precipitates
were analyzed by Western blotting with anti-V5 (A) and anti-HA (B)
to detect TORC1 and MEKK1, respectively. The input lysates were
also probed for MEKK1 (C). Similar results were also obtained from
other cell lines such as HEK293T.
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cloning of TORCs (Iourgenko et al., 2003). We first confirmed
that the expression of luciferase reporter driven by IL-8
promoter was activated by TORC1 (Figure 8, A–C, group 5
compared with group 1). Furthermore, this activation was
dependent on the CRE because disruption of CRE sup-
pressed the response to TORC1 almost completely (Figure 8,
D-–F, group 5 compared with group 1). The expression of
MEKK1 or MEKK-C alone also activated the transcription
from IL-8 promoter in a dose-dependent manner (Figure 8,
A and B, group 2–4 compared with group 1). The activation
by MEKK1 was substantially inhibited but not completely
abolished when the CRE in the IL-8 promoter was disrupted
(Figure 8, D and E, group 2–4 compared with group 1).
Importantly, coexpression of MEKK1 or MEKK-C with
TORC1 significantly enhanced transcriptional activity of
TORC1 on IL-8 promoter (Figure 8, A–B, group 6–8 com-
pared with group 5). The activity of MEKK1, MEKK-C, and
TORC1 was substantially reduced on the CRE-deficient IL-8
promoter (Figure 8, D and E, group 6–8 compared with
group 5). In addition, the kinase-dead mutant MEKK1
D1369A was unable to activate IL-8 promoter significantly
(Figure 8, C and F). Collectively, our results suggested that
MEKK1 could enhance the activity of TORC1 on CRE in the
context of IL-8 promoter.
To establish the role of TORC1 in MEKK1-induced acti-
vation of IL-8 promoter, we made use of a dominant inactive
form of TORC1. Previously, a truncated mutant of TORC1/2
comprising the N-terminal CREB-binding domain only has
been shown to have dominant interfering activity on wild-
type TORC1/2 (Bittinger et al., 2004; Xu et al., 2007). A
similar construct was made and we noted that the N-termi-
nal 152 residues of TORC1 fused to Gal4 DNA-binding
domain (i.e., GalM1 or GM1) had a more potent interfering
activity on TORC1 (Supplemental Figure S6, B compared
with A). When this GalM1 mutant was expressed in HeLa
cells, in which TORC1 is a major TORC coactivator (data not
shown), the activation of IL-8 promoter by MEKK1 or
MEKK-C was inhibited almost completely (Figure 8, G and
H). Thus, endogenous TORC1 was critically involved in
MEKK1-induced activation of IL-8 promoter.
IL-1 is a physiological inducer of IL-8 (Larsen et al., 1989)
and is also an activator of MEKK1 (Xia et al., 2000). This
prompted us to investigate whether IL-1 activates IL-8
production through TORC1 and MEKK1. However, the ac-
tivation of IL-8 production by IL-1 is a rapid process that
could not be accurately reflected by luciferase reporter as-
say. In addition, it would be desirable to measure the acti-
vation of endogenous IL-8 gene. Thus, we used semiquan-
titative RT-PCR to monitor the change of IL-8 transcript in
response to treatment with IL-1 in HeLa cells (Figure 9A).
Consistent with previous findings (Larsen et al., 1989), acti-
vation of IL-8 transcription by IL-1 peaked at 1 h after
treatment and diminished at later time points (Figure 9A,
lanes 3–5 compared with lane 2). Although expression of an
irrelevant shRNA (shGFP) did not influence the induction of
IL-8 transcript by IL-1 (Figure 9A, lane 7 comparedwith lanes
2 and 6), prior expression of shTORC1a and shTORC1b, two
independent shRNAs that were specific and effective in
suppressing the expression of TORC1 mRNA (Siu et al., 2006
and Supplemental Figure S7), led to a significant reduction
in the steady-state amount of endogenous IL-8 transcript in
HeLa cells (Figure 9A, lanes 8 and 9 compared with lanes 6
and 7). In contrast, neither shTORC1a nor shTORC1b had
any influence on the expression of the irrelevant GAPDH
transcript.
Next we also performed Northern blotting to quantify the
steady-state amounts of IL-8 mRNA. The dynamics of IL-
1–induced IL-8 transcription in HeLa cells was reassessed
and a pronounced induction was observed at 60 min after
treatment (Figure 9B, lanes 4 compared with lanes 1–3, and
lane 6 compared with lane 5). When cells were pretrans-
fected with expression plasmids for A-CREB, GalTORC1-
M1, and MEKK-KR, which are well-characterized dominant
inactive forms of CREB, TORC1, and MEKK1, respectively
(Yan et al., 1994; Ahn et al., 1998; Ching et al., 2004; Siu et al.,
2006; Xu et al., 2007), substantial reduction of IL-8 transcript
was observed (Figure 9B, lanes 7 and 8 compared with lane
3). That is to say, loss of CREB, TORC1, or MEKK1 function
as a result of the expression of dominant inactive mutant
prevented the induction of IL-8 transcription by IL-1. In
other words, endogenous CREB, TORC1, and MEKK1 were
required for IL-1–induced activation of IL-8 promoter.
To shed light on the mechanism by which TORC1 me-
diates the stimulation of IL-8 promoter by IL-1, we next
Figure 6. Colocalization of MEKK1 with TORC1.
HeLa cells were transfected with expression plasmids
for V5-tagged TORC1 and HA-tagged MEKK1 (panels
1–4), HA-tagged MEKK1 D1369A (panels 5–8), or Myc-
tagged MEKK-C (panels 9–12). TORC1 and MEKK pro-
teins were detected by fluorescein- and tetramethylrho-
damine isothiocyanate (TRITC)-conjugated secondary
antibodies, respectively. Nuclei were visualized by
DAPI staining. Transfected cells are highlighted with
arrows. Bar, 30 m.
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investigated whether IL-1 might have an impact on
MEKK1-induced phosphorylation of TORC1. Because the
induction of IL-8 transcription by IL-1 peaked at 1 h after
treatment (Figure 9, A and B), we monitored the dynamics of
TORC1 proteins in IL-1–treated HeLa cells within the first
hour (Figure 9C). Indeed, an approximately twofold eleva-
tion of phosphorylated TORC1 was found at 60 min after
treatment with IL-1 (Figure 9C, lane 4 compared with lanes
1–3). Importantly, phosphorylation of TORC1 S167A mutant
could also be induced by IL-1 (Figure 9C, lanes 5–8), sug-
gesting that the phosphorylation of TORC1 could be medi-
ated by MEKK1. Because the CMV promoter used to drive
TORC1 expression could also be stimulated by MEKK1
(Bruening et al., 1998), we also compared the levels of
TORC1 transcript in untreated and IL-1–treated transfected
cells by semiquantitative and quantitative real-time RT-PCR.
We did not notice a significant change within 1 h after
treatment (Supplemental Figure S8). In addition, similar re-
sults were also obtained when the expression of TORC1 was
driven by the SV40 promoter and enhancer (data not
shown). Thus, IL-1–induced activation of CMV promoter
and the consequent elevation of TORC1 transcript were not
a significant concern in our experimental setting.
Finally, we performed a ChIP assay to determine the
recruitment of TORC1 to the IL-8 promoter (Figure 9D). We
immunoprecipitated TORC1–DNA complex from HeLa cells
and then PCR-amplified the CRE-containing sequence in the
IL-8 promoter. A much more pronounced band of amplified
DNA was observed only when HeLa cells were treated with
IL-1 (Figure 9D, lane 4 compared with lane 3), suggesting
that IL-1 induced the recruitment of TORC1 to IL-8 pro-
moter. Because IL-1was also found to stimulate the recruit-
ment of TORC1 S167A, this process was independent of
TORC1 phosphorylation at S167. Collectively, our findings
are consistent with the model that IL-1 activates MEKK1 to
induce TORC1 phosphorylation and its subsequent recruit-
ment to IL-8 promoter.
DISCUSSION
In this study, we demonstrated a new MEKK1-mediated
signaling pathway that regulates the activity of TORC1 co-
activator in the activation of CRE-dependent transcription.
We showed that MEKK1, but not its downstream kinases
MEK1/2, ERK2, JNK, or p38, stimulated TORC1-mediated
activation of CRE in a manner that required MEKK1-in-
Figure 7. Definition of an MEKK1-responsive activation domain in TORC1. (A) A diagram of truncated TORC1 mutants. (B) Transcriptional
activity of GalTORC1 and mutants. HEK293T cells were transfected with reporter construct pGal-Luc paired with increasing amounts of
empty pM vector (vec) or an expression vector for full-length TORC1 (T1) or one of the TORC1 mutants (M1–M4) fused to Gal4 DNA-binding
domain. (C) Stimulation of GalM4 transcriptional activity by MEKK-C. HEK293T cells were transfected with progressively increasing
amounts of MEKK-C plasmid. (D) MEKK-C–induced phosphorylation of GalM4. HEK293T cells were transfected with expression plasmids
for GalM4 and MEKK-C. Cell lysate in lane 3 was treated with AP. GalM4 and MEKK-C were detected with anti-Gal4 (mouse monoclonal;
clone RK5C1 from Santa Cruz) and anti-HA antibodies, respectively. pGal4M4 represents hyperphosphorylated form of GalM4 protein.
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duced phosphorylation of TORC1, which did not occur at
S167 (Figures 1–4). Activation of TORC1 by MEKK1 was not
mediated through PKA or calcineurin (Figure 2). Instead,
MEKK1 physically associated with TORC1 (Figure 5), and
the kinase activity of MEKK1 sufficiently induced TORC1
phosphorylation in vitro and in vivo (Figures 3 and 4).
Mechanistically, MEKK1-induced phosphorylation of TORC1
in the 220-residue C-terminal activation domain (Figure 7)
promoted nuclear translocation of TORC1 and its subsequent
recruitment to CRE promoters (Figures 6 and 9). Importantly,
we provided the first evidence for the operation of this
MEKK1-TORC1 signaling pathway in the physiological activa-
tion of IL-8 promoter by IL-1 (Figures 8 and 9). Although our
findings were made with TORC1, similar results were also
obtained in experiments conducted with TORC2 and TORC3
(data not shown). Thus, our work reveals a general mechanism
for the regulation of TORC activity.
TORCs are essential coactivators of CREB and have im-
portant regulatory roles in glucose metabolism, neuronal
function, and cell growth (Takemori et al., 2007a; Dentin et
al., 2008). One well-characterized signaling pathway for reg-
ulation of TORC activity involves LKB-AMPK kinases and
targets TORCs for posttranslational modifications such as
O-linked glycosylation and polyubiquitination (Screaton et
al., 2004; Dentin et al., 2007, 2008). The phosphorylation of
TORC1 by AMPK is thought to take place at S167 equivalent
to S171 of TORC2 (Screaton et al., 2004). However, our
various experiments performed with TORC1 and TORC1
S167A yielded essentially the same results (Figures 1, 4, 8,
and 9, and Supplemental Figures S2 and S4), suggesting that
what we described in this work could be independent of
AMPK-mediated phosphorylation. Although our findings
do not exclude the possibility for cross-talk between the two
pathways, existing evidence does suggest that they respond
to different stimuli and lead to opposite consequences. In
contrast to AMPK kinases that are regulated by LKB1, AMP,
and calcium (Takemori et al., 2007a), MEKK1 is activated by
IL-1 (Figure 9). More importantly, whereas AMPK-cata-
lyzed phosphorylation of TORC1 at S167 caused sequestra-
tion of TORC1 in the cytoplasm and prevention of its tran-
scriptional activity (Screaton et al., 2004), MEKK1-induced
phosphorylation of TORC1 in the C-terminal activation do-
main of 220 amino acids promoted nuclear translocation and
its recruitment to CRE promoter (Figures 6, 7, and 9).
While our work was under review, an independent study
suggested a new mechanism for regulation of TORC2 activ-
ity by cAMP and glucose (Jansson et al., 2008). In their
model, TORC2 is inhibited by MARK2-catalyzed phosphor-
ylation at S275 and activated by calcineurin-dependent de-
phosphorylation at both S171 and S275. Although both their
and our findings support the notion that S171 phosphoryla-
tion can insufficiently account for induced translocation and
activation of TORC coactivators, it is noteworthy that the
components and consequence of the two signaling pathways
demonstrated in the two studies are still different. MARK2 is
another AMPK-related kinase and MEKK1 is a MAP3K.
Moreover, similar to phosphorylation at S171 by SIK2, phos-
phorylation of TORC2 at S275 by MARK2 sequesters the
protein in the cytoplasm and therefore inhibits transcrip-
tional activity. On the contrary, phosphorylation of TORC1
within the C-terminal region of 220 residues by MEKK1
leads to transcriptional activation (Figure 7). Hence, these
two pathways that control intracellular activity of TORC
coactivators through phosphorylation at S167/S261 and
Figure 8. Stimulation of TORC1 activity on
IL-8 promoter by MEKK1. HeLa cells were co-
transfected with reporter plasmid pIL-8-Luc
(A–C, G, and H) or pIL-8CRE-Luc (D–F) plus
progressively increasing amounts of expression
vector for MEKK1 (A and D), MEKK-C (B and
E), MEKK1 D1369A (C and F), and GalM1
(GM1; G and H).
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another site within the C-terminal activation domain likely
operate in different contexts and serve different physiologi-
cal roles. Particularly, because various cellular targets of CREB
differ in their requirement for TORCs (Ravnskjaer et al., 2007;
Xu et al., 2007), it is plausible that only a subset of CREB target
genes are regulated by MEKK1.
Here, we identified IL-8 as one of the CREB targets re-
sponsive to MEKK1 stimulation (Figure 8). In addition, as a
physiological stimulus of IL-8 production, IL-1 rapidly in-
duced MEKK1-dependent phosphorylation of TORC1 and
its subsequent recruitment to IL-8 promoter (Figure 9). IL-8
is a prototypic chemokine that plays pivotal roles in cyto-
kine signaling, tumor progression, angiogenesis and tissue
remodeling (Rossi and Zlotnik, 2000). Because of its impor-
tance and inducibility, transcriptional activation of IL-8 pro-
moter has been extensively studied (Hoffmann et al., 2002).
Nuclear factor B (NF-B) and AP1 are thought to be key
regulators of IL-8 promoter (Yasumoto et al., 1992). Plausi-
bly, the activation of IL-8 promoter by MEKK1 in the ab-
sence of TORC1 overexpression (Figure 8, A and B) was
attributed at least in part to the stimulation of NF-B and
AP1. Although a functional CRE has been identified in IL-8
promoter and its activation by TORCs have been shown
(Iourgenko et al., 2003), the physiological function of this
CRE is not understood. In this regard, our findings that
MEKK1 stimulates TORC1-dependent activation of IL-8 pro-
moter and that IL-1 induces IL-8 transcription through
phosphorylation and promoter recruitment of TORC1 reveal
a new facet in the regulation of IL-8 gene expression. It will
be of great interest to see whether other physiological and
pathological inducers of IL-8 such as tumor necrosis factor 
and Ras (Sparmann and Bar-Sagi, 2004) might also act
through MEKK1 and TORCs. In addition, the cooperation of
different activation pathways and transcription factors in-
cluding NF-B, AP1, and CREB in the activation of IL-8
promoter also merits further investigations. Likewise, iden-
tification and characterization of additional CREB target
genes that are regulated through MEKK1 and TORCs are
much warranted.
We were able to exclude the involvement of MEK1/2,
ERK2, JNK, p38, PKA, calcineurin, and several other down-
stream kinases in MEKK1-induced activation of TORC1
(Figure 2). Our results implicate a more direct role for
MEKK1 in S167- and S261-independent phosphorylation of
TORC1 (Figures 1 and 4 and Supplemental Figure S4). How-
ever, we cannot completely rule out the possibility that another
kinase tightly associated with MEKK1 in the immunoprecipi-
tate might be responsible for the modification of TORC1. To
establish direct phosphorylation of TORC1 by MEKK1, an in
vitro kinase assay should be performed with functional recom-
binant MEKK1 protein free of contaminating kinases.
Although we presented evidence that MEKK1-induced
phosphorylation of TORC1 occurred within the 220-residue
activation domain at the C-terminus (amino acids 431–650;
Figure 7), but not at S167 (Figures 1 and 4 and Supplemental
Figure S4) or S261, our multiple attempts to determine the
exact phosphorylation site(s) by using mass spectrometry
and site-directed mutagenesis were unsuccessful. TORC1 is
likely phosphorylated at multiple sites (Screaton et al., 2004;
Jansson et al., 2008) and phosphorylation at any site is often
substoichiometric. Hence, in future experiments it will be
crucial to increase the yield of phosphorylated TORC1 upon
stimulation with MEKK1 and to achieve a higher stoichiom-
etry of MEKK1-induced phosphorylation.
Our results obtained from luciferase reporter assays (Fig-
ures 1 and 8 and Supplemental Figure S1) and confocal
microscopy (Figure 6) consistently supported the notion that
Figure 9. IL-1–induced activation of IL-8 promoter through TORC1.
(A) Requirement of TORC1 for IL-1–induced production of IL-8. In lanes
1–5, HeLa cells were treated with 10 ng/ml IL-1 for the indicated dura-
tion of time. In lanes 6–9, cells were transfected with empty shRNA
expression vector (vec) and expression plasmids for shGFP, shTORC1a,
and shTORC1b, respectively, before treatment with 10 ng/ml IL-1 for
1 h. IL-8 and GAPDH transcripts were analyzed by semiquantitative
RT-PCR. The ability of shTORC1a and shTORC1b to knockdown TORC1
expression and activity was confirmed by RT-PCR analysis of TORC1
transcript and by luciferase assay (Siu et al., 2006 and Supplemental Figure
S7). (B) Requirement of CREB, TORC1, andMEKK1 for IL-1 induction of
IL-8. In lanes 1–4, HeLa cells were treated with 10 ng/ml IL-1 for the
indicateddurationof time. In lanes 7–9, cells transfected, respectively,with
expression vectors for A-CREB, GalTORC1-M1, and MEKK-KR were
treatedwith 10 ng/ml IL-1 for 60min. IL-8 andGAPDHtranscriptswere
analyzed by Northern blotting. (C) IL-1–induced phosphorylation of
TORC1 is independent of S167. HeLa cells were transfected with expres-
sion plasmid for V5-tagged TORC1 (lanes 1–4) or TORC1 S167A (lanes
5–8). Cells were treatedwith 10 ng/ml IL-1 for 0–60min as indicated at
48 h after transfection. Cell lysates were immunoblotted for TORC1 using
anti-V5. Similar resultswere also obtained if cellswere transfectedwith an
expression plasmid for GalTORC1 driven by SV40 promoter and en-
hancer. (D) TORC1 recruitment to the IL-8 promoter. HeLa cells were
transfectedwith expression plasmid for V5-tagged TORC1 (lanes 3 and 4)
or TORC1 S167A (lanes 7 and 8). Cells were treated with 10 ng/ml IL-1
for 1 hbefore harvest (lanes 2, 4, 6, and8). TheDNA/TORC1 complexwas
immunoprecipitated using anti-V5 antibody and the IL-8 sequence was
PCR-amplified.
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MEKK-C was more active than full-length MEKK1 in induc-
ing TORC1 nuclear translocation and transcriptional activa-
tion. These data are also in agreement with the dominant
active property of MEKK-C (Gibson et al., 1999) and the
negative regulatory function of the N-terminal domain of
MEKK1 (Xu et al., 1996; Lu et al., 2002; Witowsky and John-
son, 2003). However, we also noted that MEKK1 and
MEKK-C exhibited comparable activity to induce phosphor-
ylation of TORC1 as analyzed by electrophoretic mobility
shift of TORC1 proteins (Figures 3 and 4, and Supplemental
Figures S3 and S4). Generally, luciferase reporter assays are
highly sensitive and produce high-resolution quantitative
data for comparison. In contrast, the analysis of phosphor-
ylation by electrophoretic mobility shift might be less accu-
rate and less quantitative. In light of this, it is not too
surprising that a higher activity of MEKK-C in phosphory-
lating TORC1 was not observed when hyperphosphorylated
TORC1 was analyzed by electrophoresis (Figures 3 and 4,
and Supplemental Figures S3 and S4).
Although our findings support the notion that MEKK1
induces nuclear translocation and promoter recruitment of
TORC1 (Figures 6 and 8), exactly how MEKK1-induced
phosphorylation of TORC1 might influence its nuclear import,
nuclear export as well as transcriptional activity remains elu-
sive. Moreover, whether and how MEKK1-induced phosphor-
ylation might modulate other forms of post-translational mod-
ifications of TORC1 such as ubiquitination and O-lined
glycosylation (Dentin et al., 2007, 2008) have not been formally
addressed. On the other hand, whether and how other stim-
uli of CREB including cAMP and calcium might influence
MEKK1-induced phosphorylation of TORC1 should also be
explored. Generally, both MEKK1 and TORCs represent
important hubs for signal integration and diversification. It
will be of great interest to identify and characterize their
upstream modulators and downstream effectors in the acti-
vation of CRE-driven transcription.
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